NASDAQ: KLTOKlotho Neurosciences Inc Stock
$0.16-0.01 (-5.88%)
Updated May 8, 2025
KLTO Price
$0.16
Fair Value Price
-$0.01
Market Cap
$4.56M
52 Week Low
$0.11
52 Week High
$8.11
P/E
-0.5x
P/B
3.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.07
Operating Cash Flow
-$3M
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KLTO Overview
Redwoods Acquisition Corporation is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, stock purchases, recapitalizations, reorganizations, or other similar combinations with one or more businesses. In intends to target the carbon neutral and energy storage industries. Redwoods Acquisition was incorporated in 2021 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KLTO's potential to beat the market
- KLTO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KLTO
RankedUnranked of 457
RankedUnranked of 457
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.89 | A | |
| $42.51 | A | |
| $8.11 | A |
Be the first to know about important KLTO news, forecast changes, insider trades & much more!
KLTO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KLTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KLTO ($0.16) is overvalued by 1,580.48% relative to our estimate of its Fair Value price of -$0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KLTO ($0.16) is not significantly undervalued (1,580.48%) relative to our estimate of its Fair Value price of -$0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KLTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KLTO due diligence checks available for Premium users.
Valuation
KLTO fair value
Fair Value of KLTO stock based on Discounted Cash Flow (DCF)
Price
$0.16
Fair Value
-$0.01
Undervalued by
1,580.48%
KLTO ($0.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KLTO ($0.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KLTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KLTO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.5x
Industry
-168.76x
Market
24.22x
KLTO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.85x
Industry
4.15x
KLTO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KLTO's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%
KLTO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.5M
Liabilities
$1.3M
Debt to equity
1.07
KLTO's short-term liabilities ($1.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KLTO's short-term assets ($157.81k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KLTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$944.2k
Investing
$0.0
Financing
$957.0k
KLTO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KLTO vs Biotech Stocks
Klotho Neurosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.